ArticleCancer research2019
Positron Emission Tomography Detects
Article in Cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Dual-labeled anti-GD2 targeted probe for intraoperative molecular imaging of neuroblastoma.Journal of translational medicine · 2024Article
- Therapeutic efficacy of an alpha-particle emitter labeled anti-GD2 humanized antibody against osteosarcoma-a proof of concept study.European journal of nuclear medicine and molecular imaging · 2024Article
- Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- GD2-targeting therapy: a comparative analysis of approaches and promising directions.Frontiers in immunology · 2024Review
- Article
- Review
- Advances in PET imaging of cancer.Nature reviews. Cancer · 2023Review
- EVI2B Is a Prognostic Biomarker and Is Correlated with Monocyte and Macrophage Infiltration in Osteosarcoma Based on an Integrative Analysis.Biomolecules · 2023Article
- Anti-GD2 antibody for radiopharmaceutical imaging of osteosarcoma.European journal of nuclear medicine and molecular imaging · 2022Article
- Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors.Journal for immunotherapy of cancer · 2022Article
- A multimodal imaging workflow for monitoring CAR T cell therapy against solid tumor from whole-body to single-cell level.Theranostics · 2022Article
- Translational immunoPET imaging using a radiolabeled GD2-specific antibody in neuroblastoma.Theranostics · 2022Article
- Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness.Theranostics · 2022Review
- Novel Tracers and Radionuclides in PET Imaging.Radiologic clinics of North America · 2021Review
- State of the Art in Radiolabeling of Antibodies with Common and Uncommon Radiometals for Preclinical and Clinical Immuno-PET.Bioconjugate chemistry · 2021Article
- Immunotherapy for sarcomas: new frontiers and unveiled opportunities.Journal for immunotherapy of cancer · 2021Review
- Review
- The Current Status and Future Potential of Theranostics to Diagnose and Treat Childhood Cancer.Frontiers in oncology · 2020Review
- Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy.Frontiers in oncology · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
The cell membrane glycolipid GD2 is expressed by multiple solid tumors, including 88% of osteosarcomas and 98% of neuroblastomas. However, osteosarcomas are highly heterogeneous, with many tumors exhibiting GD2 expression on <50% of the individual cells, while some tumors are essentially GD2-negative. Anti-GD2 immunotherapy is the current standard of care for high-risk neuroblastoma, but its application to recurrent osteosarcomas, for which no effective therapies exist, has been extremely limited. This is, in part, because the standard assays to measure GD2 expression in these heterogeneous tumors are not quantitative and are subject to tissue availability and sampling bias. To address these limitations, we evaluated a novel, sensitive radiotracer [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.